Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CRISPR Therapeutics AG (CRSP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results -PDUFA target action date of December 8, 2023, for SCD and March 30, 2024, for TDT-"
06/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "of der CRISPR Therapeutics AG CRISPR Therapeutics AG with registered office in mit Sitz in Zug Zug I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sitz, Dauer und Zweck der Gesellschaft Art. 1 Corporate Name, Principal Office and Duration Art. 1 Firma, Sitz und Dauer Under the name CRISPR Therapeutics AG Unter der Firma CRISPR Therapeutics AG there exists a Company which is subject to the provisions of art. 620 et seq. of the Swiss Code of Obligations with registered office in Zug. The duration of the Company is unlimited. besteht für unbeschränkte Dauer eine Aktiengesellschaft gemäss Art. 620 ff. OR mit Sitz in Zug. Art. 2 Purpose Art. 2 Zweck The purpose of the Company is the research and development in the field of pharmaceutical pro..."
06/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Accepts Biologics License Applications for exagamglogene autotemcel for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia - First CRISPR gene-editing filings to be accepted for review by FDA",
"Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association Congress - Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - - Data continue to demonstrate transformative and durable benefit - - Safety profile consistent with busulfan conditioning and autologous hematopoietic stem cell transplant –"
05/08/2023 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results"
04/03/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia -EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023-"
03/29/2023 8-K Quarterly results
03/27/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "[***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601 of Regulation S-K. NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND CRISPR THERAPEUTICS AG Non-excLusive LICENSE AGREEMENT This NON-EXCLUSIVE LICENSE AGREEMENT is entered into as of March 23, 2023 by and between Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG . Vertex and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” RECITALS WHEREAS, CRISPR possesses certain Patents, Know-How, technology and exper...",
"Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes -Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- -CRISPR Therapeutics to receive $100M upfront payment plus milestone and royalty payments on potential future gene-edited hypoimmune T1D products -"
03/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Proprietary Information and Inventions Agreement 16",
"Investor Contact:"
11/01/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
09/27/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 - Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 – - EMA and MHRA submissions are on track for Q4 2022 – - Exa-cel granted Fast Track, Regenerative Medicine Advanced Therapy and Orphan Drug designations in the U.S., and Priority Medicines and Orphan Drug designations in Europe -"
08/08/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/15/2022 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results - More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing patients in the pivotal trial of CTX110™, targeting CD19+ B-cell malignancies; additional data expected to report in 2022- -Top-line data expected to report in 1H2022 for ongoing CTX120™and CTX130™ clinical trials- -First patient dosed in Phase 1 clinical trial of VCTX210 for the treatment of type 1 diabetes - ZUG, Switzerland and CAMBRIDGE, Mass., February 15, 2022"
12/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/22/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to CTX110 ™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies"
11/03/2021 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results -Achieved target enrollment in CTX001 clinical trials for beta thalassemia and sickle cell disease ; regulatory submissions planned for late 2022- -Reported positive results from the ongoing Phase 1 CARBON clinical trial evaluating the safety and efficacy of CTX110™ for CD19+ B-cell malignancies; enrollment continues, with potential registrational trial incorporating consolidation dosing expected to initiate in Q1 2022- -Implementing consolidation dosing protocols for CTX120™ and CTX130™ clinical trials; enrollment continues, with top-line data expected to report in 1H 2022- -Regenerative medicine and in vivo programs continue to progress and remain on track- ZUG, Switzerland and CAMBRIDGE, Mass.,..."
10/14/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Employment Agreement, by and between CRISPR Therapeutics, Inc. and Brendan Smith",
"CRISPR Therapeutics Announces Transition of Chief Financial Officer"
10/12/2021 8-K Investor presentation
Docs: "CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110 ™ in Relapsed or Refractory CD19+ B-cell malignancies",
"Selected Slides from Presentation: Updated Results from the Phase 1 CARBON Trial of CTX110™"
07/29/2021 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results - More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021-"
06/14/2021 8-K Quarterly results
06/11/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
04/20/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
01/15/2021 8-K Quarterly results
12/17/2020 8-K Other Events  Interactive Data
12/11/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Walder Wyss AG"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy